Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors
ContributorsFernandez, Eugenio; Vernet, Rémi; Charrier, Emily Pauline; Migliorini, Denis; Urwyler, Muriel; Belkouch, Marie-Claude; Von Rohr, Olivier; Saingier, Valentin; Ancrenaz, Virginie; Grandjean, Nicole; Lafferma, Elisabeth; Lavalliere, Emmanuel; Rubin, Olivier; Villard, Jean; Grogg, Julien; Mach, Nicolas
Presented atESMO Congress 2022, Paris, 9-13 septembre 2022
Publication date2022-09
NotePublié dans : Annals of oncoloy, 2022, 33(S7) : S891
Affiliation
Research group
Citation (ISO format)
FERNANDEZ, Eugenio et al. Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors. In: ESMO Congress 2022. Paris. 2022. doi: 10.1016/j.annonc.2022.07.888
Main files (1)
Presentation
Secondary files (1)
Identifiers
- PID : unige:177983
- DOI : 10.1016/j.annonc.2022.07.888
